PDF
Full
Outline
To analyze the association between Body Roundness Index (BRI) and to cardiometabolic comorbidities among individuals aged 35-75 years in Zhejiang Province.
Residents aged 35-75 years recruited in the 2022 China National Nutrition and Health Survey (Zhejiang region) were selected as the study population. Statistical analyses were performed using R 4.3.3 and SPSS 30.0. The χ2 test and logistic regression were used to evaluate the impact of BRI on cardiometabolic diseases.
The overall prevalence rates of hypertension, diabetes, dyslipidemia, coronary heart disease, stroke, and cardiometabolic comorbidities in Zhejiang residents aged 35-75 years were 41.43%, 15.46%, 40.07%, 1.20%, 0.78%, and 27.99%, respectively. Logistic regression analysis showed that after adjusting for confounders, individuals in the fourth quartile (Q4) of BRI had a higher risk of hypertension (OR=4.10, 95%CI: 3.11-5.38）, diabetes (OR=3.18, 95%CI: 2.20-4.61), dyslipidemia (OR=3.84, 95%CI: 2.95-5.00), coronary heart disease (OR=3.40, 95%CI: 0.74-15.71), stroke (OR=1.10，95%CI: 0.34-3.56) and cardiometabolic comorbidities (OR=5.20, 95%CI: 3.76-7.13) compared with the first quartile (Q1). Female participants (OR=1.43, 95%CI: 1.28-1.60) had a lower risk compared to males (OR=1.70，95%CI: 1.48-1.96). Significant interaction effects of age and smoking on the risk of cardiometabolic comorbidities were observed, with the risk significantly higher in middle-aged adults (35-54 years). In a population with normal BMI, ROC curve analysis indicated that BRI was superior to BMI in predicting the risk of CMM, however, both AUC values were below 0.7, suggesting that the predictive ability remains weak.
Higher BRI levels were positively associated with cardiometabolic comorbidities. To identify high-risk populations for cardiometabolic comorbidities early, targeted management and intervention strategies should be implemented to reduce the burden of cardiometabolic diseases. However, caution is warranted when promoting the use of BRI in public health and clinical practice, as further research is needed to validate its effectiveness.
PDF
51
21
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
